Market Cap (In USD)
9.16 Million
Revenue (In USD)
477 Thousand
Net Income (In USD)
-11.57 Million
Avg. Volume
851.09 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.84-10.8
- PE
- -
- EPS
- -
- Beta Value
- 1.272
- ISIN
- US09060U5074
- CUSIP
- 09060U507
- CIK
- 925741
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Peter A. Altman Ph.D.
- Employee Count
- -
- Website
- https://www.biocardia.com
- Ipo Date
- 1996-11-13
- Details
- BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
More Stocks
-
3130104 Corporation
3130
-
BLUESTARCOBlue Star Limited
BLUESTARCO
-
LU
-
BHAGCHEM
-
2485Zinwell Corporation
2485
-
7736HUSHAN
7736
-
4142
-
2855